Events

News

  1. G+FLAS
  2. Notices
  3. News

ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement

  • News
  • Count8066
  • Date2021.02.24

G+FLAS Life Sciences is applying CRISPR technology to develop research tools and reagents


Dublin, Ireland and Seoul, Korea, 23 February 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and G+FLAS Life Sciences, Inc. (G+FLAS), a biotechnology company developing research tools and reagents associated with CRISPR technology, today announced a non-exclusive license agreement granting G+FLAS access to ERS Genomics’ CRISPR/Cas9 patent portfolio.


G+FLAS supports research organizations by providing CRISPR-related biological research services, tools, and reagents. The Company produces all research tools and reagents under ISO 13485 and ISO 9001 and is applying CRISPR PLUS technology to the development of drugs and production of CRISPR genome edited plants in a non-GMO way.


ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.


“G+FLAS is developing genome editing applications using CRISPR/Cas9 that will further expand the reach of this important gene editing tool,” said Eric Rhodes, CEO of ERS Genomics. “We are pleased to provide access to this Nobel Prize winning technology and look forward to seeing G+FLAS continue in its mission.”


“We are very excited to sign this licensing agreement with ERS Genomics, to build on the strength of our existing platform and drive our future growth,” said Sunghwa Choe, CEO of G+FLAS Life Sciences. “Based on our advanced CRISPR PLUS research technology and global-standard production process, we will continue to innovate to meet our clients’ needs, to make differences in their discovery processes.”


Financial details of the agreement are not disclosed.


ENDS


-------------------------------------------------------------------------------------------------------------------------------------------------------------


For high resolution images please contact Zyme Communications


Media contact:

Katie Odgaard

Zyme Communications

Tel: +44(0)7787 502 947

Email: katie.odgaard@zymecommunications.com


Contact G+FLAS Life Sciences, Inc.:

Junhee Lee

BD Manager

Tel: +82-704469-8315

Email: jaybrant.lee@gflas.com


To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy please click here.



About ERS Genomics www.ersgenomics.com


ERS Genomics is a biotechnology company based in Dublin, Ireland. The company was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.com.


Eric Rhodes, CEO, ERS Genomics



About G+FLAS Life Sciences, Inc. http://eng.gflas.com/en/


G+FLAS Life Sciences, Inc. is a biotechnology company based in Seoul, Korea. The company was founded by Sunghwa Choe, professor at Seoul National University, to provide global scientists with CRISPR/Cas9-enabled products made of their proprietary CRISPR PLUS and Non-GMO plant genome editing technologies. Products available for non-exclusive licensing include CRISPR PLUS genome editing enzymes that possess enhanced indel efficiency while lowering off-target effects, non-GMO method of plant genome engineering, and humanized Nicotiana benthamiana plants whose protein glycosyltransferases were deleted to produce glyco-optimized biopharmaceuticals such as monoclonal antibodies and recombinant subunit vaccines. For additional information please visit http://eng.gflas.com/en/.


Sunghwa Choe, CEO, G+FLAS Life Sciences, Inc.

Go to List